BIOVIE INC

BIVI15 Feb 2025
Healthcare
$1.77
+0.04 (+3.67%)
Lowest Today
$1.77
Highest Today
$1.87
Today’s Open
$1.77
Prev. Close
$1.77
52 Week High
$18.9
52 Week Low
$1.04
To Invest in BIOVIE INC

BIOVIE INC

Healthcare
BIVI15 Feb 2025
+0.04 (+3.67%)
1M
3M
6M
1Y
5Y
Low
$1.77
Day’s Range
High
$1.87
1.77
52 Week Low
$1.04
52-Week Range
52 Week High
$18.9
1.04
1 Day
-
1 Week
-6.8%
1 month return
-11.22%
3 month return
-43.75%
6 month return
-17.59%
1 Year return
+50.84%
3 Years return
-43.84%
5 Years return
-82.2%
10 Years return
-
Institutional Holdings
Belfund SICAV Belinvest Equity A USD Acc
0.56
Fidelity Extended Market Index
0.39
DRIVE WEALTH MANAGEMENT, LLC
0.34
Vanguard Group Inc
0.32
Vanguard Institutional Extnd Mkt Idx Tr
0.27
Vanguard Total Stock Mkt Idx Inv
0.23
SMH Capital Inc.
0.23

Market Status

Fundamentals
Market Cap
31.92 mln
PB Ratio
1.33
PE Ratio
0
Enterprise Value
7.9 mln
Total Assets
25.21 mln
Volume

Company Financials

Fund house & investment objective

Company Information
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease. The company develops BIV201 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
Organisation
BIOVIE INC
Employees
14
Industry
Biotechnology
CEO
Mr. Cuong Viet  Do M.B.A.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step